ALK and lung cancer: In this study, we validated the applicability of lung cancer PDX models in preclinical screening of the targeted anticancer therapeutics, using five samples, including two tumor tissue samples (033 T, 694 T as negative control), two lung cancer cell lines (H1975 (EGFR mutation; L858R/T790 M), H2228 (EML4-ALK)), and a normal lung tissue sample.